Abstract
Methyl aminolevulinate photodynamic therapy (MAL-PDT) is utilized in several countries for the treatment of basal cell carcinoma, but allergic sensitization has been reported by the manufacturer. To the best of our knowledge, we report the first case of urticaria following MAL-PDT in a patient with nevoid basal cell carcinoma syndrome. Prophylactic use of antihistamines may allow continued use of MAL-PDT in this setting.
MeSH terms
-
Aminolevulinic Acid / adverse effects
-
Aminolevulinic Acid / analogs & derivatives*
-
Aminolevulinic Acid / therapeutic use
-
Basal Cell Nevus Syndrome / drug therapy
-
Basal Cell Nevus Syndrome / pathology
-
Carcinoma, Basal Cell / drug therapy
-
Carcinoma, Basal Cell / pathology
-
Female
-
Humans
-
Middle Aged
-
Photochemotherapy / adverse effects*
-
Photochemotherapy / methods
-
Photosensitizing Agents / adverse effects*
-
Photosensitizing Agents / therapeutic use
-
Skin Neoplasms / drug therapy
-
Skin Neoplasms / pathology
-
Urticaria / etiology*
Substances
-
Photosensitizing Agents
-
methyl 5-aminolevulinate
-
Aminolevulinic Acid